title: Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: evidence for an impaired cardiopulmonary baroreflex function.
abstract: High doses of nitroglycerin may decrease portal pressure in patients with cirrhosis with untoward effects such as arterial hypotension and a decrease in systemic O2 uptake. In the present study, low doses of nitroglycerin (7 to 15 micrograms per min, i.v.) were administered in 11 patients with cirrhosis in order to unload cardiopulmonary baroreceptor--one of the possible mechanisms by which nitroglycerin may improve splanchnic hemodynamics--and moreover to avoid deleterious systemic effects. Nitroglycerin significantly decreased right atrial pressure (-35%) and pulmonary wedged pressure (-27%) with significant increase in plasma norepinephrine concentration (+23%), which indicated that cardiopulmonary baroreceptor unloading was achieved. Changes in systemic hemodynamics were slight, although significant, with a decrease in arterial pressure (-8%) and an increase in heart rate (+8%); this indicates a minimal effect on high-pressure baroreflexes. In contrast, no significant change was observed in hepatic venous pressure gradient, hepatic blood flow and azygos blood flow. However, the fraction of cardiac output reaching the azygos system significantly increased by 18%. Plasma renin activity did not change significantly. Moreover, O2 transport and uptake were significantly decreased. These findings show that low doses of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis. These results suggest an impaired cardiopulmonary baroreflex function which is probably located on the efferent arch.
authors.affiliation: Unité de Recherches de Physiopathologie Hépatique (INSERM U-24), Hôpital Beaujon, Clichy, France.
authors.forename: R
authors.initials: R
authors.lastname: Moreau
authors.forename: D
authors.initials: D
authors.lastname: Roulot
authors.forename: A
authors.initials: A
authors.lastname: Braillon
authors.forename: C
authors.initials: C
authors.lastname: Gaudin
authors.forename: A
authors.initials: A
authors.lastname: Hadengue
authors.forename: Y
authors.initials: Y
authors.lastname: Bacq
authors.forename: D
authors.initials: D
authors.lastname: Lebrec
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D006329:Heart Conduction System / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008168:Lung / Q000294:innervation / Q000503:physiopathology*; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D011311:Pressoreceptors / Q000503:physiopathology*; D012018:Reflex / Q000502:physiology; D013152:Splanchnic Circulation / Q000187:drug effects*
chemical_list: D005996:Nitroglycerin